Company / Free Cash Flow per Share
CRISPR Therapeutics AG Free Cash Flow per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow per Share
-$3.61
FY2025
5-year range
-$6.79 / $5.94
FY2021-FY2025
Trend
-113.8%
vs FY2024
Sector context
#165 of 193
Health Care
What the data says
CRISPR Therapeutics AG's free cash flow per share of $-3.61 is lower than 85% of companies in the Health Care sector (FY2025). Free Cash Flow per Share has fluctuated over the past 10 years, ranging from $-6.79 in FY2022 to $5.94 in FY2021.
Based on SEC 10-K filings.
-3.61 in FY2025.
Declined from $-3.37 to $-3.61 over the past 2 years.
Health Care sector context is included.
Free Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 15% in Health CareTop 85% of 193This company -$3.61 Sector average -$19.72
▼
+81.7% above sector average
Key checks
Key Insights
- In FY2025, free cash flow per share decreased 113.8% year-over-year.
- Ranks #165 out of 193 companies in the Health Care sector.
- Peak free cash flow per share was recorded in FY2021.
- Lowest free cash flow per share in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$3.61 | -113.8% |
| FY2024 | -$1.69 | +49.9% |
| FY2023 | -$3.37 | +50.3% |
| FY2022 | -$6.79 | -214.3% |
| FY2021 | $5.94 | +271.0% |
| FY2020 | -$3.47 | -460.2% |
| FY2019 | $0.96 | +170.0% |
| FY2018 | -$1.38 | -193.8% |
| FY2017 | $1.47 | +236.4% |
| FY2016 | -$1.08 | -109.3% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026